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ABSTRACT
The mechanisms of cisplatin resistance, one of the major limitations of current 
chemotherapy, has only partially been described. We previously demonstrated 
that cisplatin-resistant ovarian cancer cells (C13), are characterized by reduced 
mitochondrial activity and higher glucose-dependency when compared to the cisplatin-
sensitive counterpart (2008). In this work we further characterized the role of 
metabolic transformation in cisplatin resistance. By using transmitochondrial hybrids 
we show that metabolic reprogramming of cisplatin-resistant cell is not caused by 
inherent mtDNA mutations. We also found that C13 cells not only present an increased 
glucose-uptake and consumption, but also exhibit increased expression and enzymatic 
activity of the Pentose Phosphate pathway (PPP) enzyme Glucose-6-Phosphate 
Dehydrogenase (G6PDH). Moreover, we show that cisplatin-resistant cells are 
more sensitive to G6PDH inhibition. Even if the metabolomic fingerprint of ovarian 
cancer cells remains to be further elucidated, these findings indicate that PPP offers 
innovative potential targets to overcome cisplatin resistance.
INTRODUCTION
Cisplatin is one of the most potent anticancer agents 
used in the treatment of various solid tumors including 
testicular, lung and ovarian cancer [1]. Despite the 
chemotherapeutic advances of the last decades, cisplatin 
still remains the first-line chemotherapeutic agent against 
epithelial malignancies, used alone or in combination 
with radiotherapy and/or other anticancer compounds. 
Cisplatin has been shown to induce the formation of 
inter- and intra-strand nuclear DNA (nDNA) cross-links 
that, by hindering both RNA transcription and DNA 
replication, lead to cell cycle arrest and apoptosis [2]. 
Cisplatin has also been shown to bind to mitochondrial 
DNA (mtDNA), which, unlike nDNA, is more susceptible 
to the onset of mutations that lead to mitochondrial 
dysfunction, oxidative stress and mitochondria-dependent 
apoptosis [3, 4, 5]. The cisplatin therapeutic effectiveness 
is limited by side effects (ototoxicity, nephrotoxicity and 
neurotoxicity) [6] and by the emergence of resistance [7], 
a multi-factorial phenomenon, linked to reduced drug 
accumulation, inactivation by thiol-containing species, 
increased repair of platinum-DNA adducts, enhanced 
tolerance to cisplatin adducts and desensitization to cell 
death pathways [8, 9, 10]. These mechanisms are cell line-
dependent, so that a particular tumor may exhibit one, two 
or even all the above-mentioned mechanisms [11].
In our previous studies we demonstrated that 
cisplatin-resistant ovarian cancer cells exhibit lower levels 
of Reactive Oxygen Species (ROS) and increased steady 
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state levels of reduced glutathione (GSH) [12] suggesting 
that cisplatin-resistance can also be associated with the 
variation of intracellular redox status. It is well established 
that GSH plays a key role in the antioxidant capabilities of 
cancer cells, but it is important to remember that GSH also 
acts forming complexes with cisplatin, thereby reducing 
the amount of intracellular drug available for interaction 
with all nucleophilic sites [13].
Cancer cells undergo profound metabolic changes 
required to fuel the biosynthetic demands of cell 
growth and division [14, 15] and to maintain the redox 
homeostasis. This metabolic rewiring is orchestrated 
by oncogenes and tumor suppressors, which fine tune 
several metabolic pathways, including glycolysis, 
oxidative phosphorylation, the pentose phosphate 
pathway and glutaminolysis [16]. Indeed, the increase 
in glucose metabolism, that hallmarks most cancer cells, 
is instrumental not only for ATP generation or for the 
synthesis of nucleotides and amino acids, but also for 
the maintenance of redox homeostasis via the NADPH-
producing Pentose Phosphate Pathway (PPP) [17]. The 
rate-limiting and “gatekeeper” enzyme of the PPP is 
glucose-6-phosphate dehydrogenase (G6PDH), whose 
activity is regulated by the availability of its substrate and 
by the NADP+/NADPH ratio [18] and directly reflects 
the partitioning of glucose utilization between glycolysis 
and oxidative PPP [19]. However, whether the metabolic 
reprogramming of cancer supports cisplatin resistance is 
currently unknown.
To shed some light on the metabolic determinants 
of cisplatin resistance, we had investigated the metabolic 
changes that occur in cisplatin–resistant ovarian cancer 
cells (C13), finding that they exhibit reduced oxygen 
consumption and increased dependency on glucose, when 
compared to their cisplatin-sensitive counterpart (2008) 
[20]. In this work we have further characterized the role 
of metabolic transformation in cisplatin resistance. We 
show that cisplatin induces deregulation of mitochondrial 
function in resistant cells, in accord with their increased 
usage of glucose, and that cisplatin-resistant cells rely 
on the PPP to overcome cisplatin cytotoxicity. We also 
demonstrate that the inhibition of the limiting enzyme of 
the PPP, G6PDH, restores cisplatin sensitivity in cisplatin-
resistant cells.
RESULTS
Role of mtDNA polymorphisms in 
cisplatin resistance
We initially investigated whether the mitochondrial 
dysfunction observed in cisplatin-resistant cells is a 
consequence of the damaging effects of cisplatin on 
mtDNA. To this aim, the mtDNA of C13 cells and 
of their cisplatin-sensitive counterpart 2008, was 
sequenced (Table 1). These analyses revealed three major 
polymorphisms in C13 cells: 8156 G>T, 12018 C>T, 
13828 C>T. Their putative pathogenicity was assessed 
by PolyPhen (http://genetics.bwh.harvard.edu/pph2/), 
a software application that predicts the impact of an 
amino acid substitution on the structure and function of 
a protein. The predicted pathogenicity of the 8156 G>T 
and 13828 C>T polymorphisms was modest, whereas the 
12018 C>T polymorphism resulted mildly pathogenic. 
In order to investigate if these mtDNA polymorphisms 
contributed to the altered mitochondrial function and 
cisplatin resistance, we generated trans-mitochondrial 
cytoplasmic hybrids (cybrids) (Supplementary Figure 1A 
for a schematic representation of the experiment). 
Interestingly, the cybrid lines (H2008 and HC13) 
were equally sensitive to cisplatin, as demonstrated by 
trypan blue exclusion assay and by Annexin V assay 
(Supplementary Figure 1B–1C). In line with our previous 
observations, cisplatin-resistant C13 cells presented lower 
oxygen consumption (Figure 1A) and lower mitochondrial 
potential (Figure 1B) when compared to 2008 cells. 
Interestingly, both respiration and mitochondrial potential 
defects were restored in the cybrid cell line HC13 and were 
comparable to the original 2008 cells (Figure 1A–1B). We 
further assessed the presence of mitochondrial dysfunction 
in C13 cells and in cybrid cell lines by growing cells in 
galactose medium. Of note, C13 cells were extremely 
sensitive to these culture conditions (Figure 1C), whereas 
their viability was not affected by long-term incubation 
with the Complex I inhibitor rotenone (Figure 1D). 
In further support of the restoration of mitochondrial 
function in cybrids, growth of HC13 cells was not 
affected by galactose, and HC13 cells became sensitive to 
rotenone (Figure 1C–1D). Together, these results suggest 
that the mitochondrial polymorphisms found in C13 cells 
do not directly contribute to the observed mitochondrial 
dysfunction and do not play a role in cisplatin resistance.
Cisplatin-resistant cells exhibit defects in 
mitochondrial morphology and a reduction in 
mitochondrial mass
We wanted to investigate whether decreased 
oxygen consumption observed in C13 cells was caused 
by a decrease in mitochondrial mass. To this aim, cells 
were stained with mitotracker green (MTG), a potential-
independent mitochondrial probe, and mitochondrial mass 
was analysed using confocal imaging. Of note, while the 
mitochondrial network of C13 cells appeared scattered and 
less structured than in 2008 cells (Figure 2A, left panels), 
no differences in mitochondrial morphology between 
H2008 and HC13 were observed (Figure 2A, right panels). 
Importantly, C13 cells showed a dramatic decrease in 
mitochondrial mass measured by Nonyl-Acridine Orange 
(Figure 2B), which was consistent with a decrease in MTG 
staining with respect to their 2008 counterpart (Figure 2C). 
Since the expression of genes involved in mitochondrial 
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biogenesis, except for PGC-1β, was not significantly 
different between C13 and 2008 (Figure 2D), we reasoned 
that the striking reduction in mitochondrial mass could be 
caused by induction of mitochondrial specific autophagy 
(mitophagy). Indeed, C13 cells exhibited a marked 
increase in LC3 staining (Figure 2E), associated to a 
significant overexpression of BNIP3 (Figure 2F), two key 
markers of activated autophagy. These results indicate that 
cisplatin-resistant cells exhibit defects in mitochondrial 
morphology and a reduction in mitochondrial mass, which 
are potentially associated to an increased activation of 
mitophagy.
Deregulation of glucose and glutamine 
metabolism in cisplatin-resistant cells
In line with a compensatory activation of glycolysis 
in the presence of mitochondrial defects, C13 cells 
exhibited increased glucose uptake (Figure 3A). Among 
the glycolytic enzymes investigated, only the glucose 
transporter GLUT1 was up-regulated in these cells 
(Figure 3B). Of note, cisplatin-resistant cells exhibited 
higher sensitivity to glucose deprivation (Figure 3C) 
and the incubation with the glycolysis inhibitor 
2-Deoxyglucose (2DG) led to significant cell death of 
these cells (Figure 3D). To support these data we used 
also another cancer cell line (human cervix squamous cell 
line, A431) and its relative cisplatin resistant counterpart 
(A431pt). A431pt, similarly to C13, presented a higher 
glucose-dependency, increased GLUT1 expression, and 
major sensitivity to galactose medium (Supplementary 
Figure 2A–2D). Together, these results show that cisplatin-
resistant cells increase their demands of glucose and are 
more sensitive to inhibition of glycolysis, when compared 
to the cisplatin-sensitive counterpart.
Glutamine is a major source of carbons for 
the mitochondria of cancer cells [21, 22]. In order 
to investigate the biosynthetic role of glutamine, we 
incubated C13 and 2008 cells with uniformly labelled 
[U-13C]glutamine and analysed the isotopologue 
distribution of tricarboxylic acid (TCA) cycle 
intermediates. While the total pool of some TCA cycle 
intermediates, including succinate and malate, was lower 
in C13 than in 2008 cells (Figure 4A), the incorporation 
Table 1: mtDNA sequence of human ovarian cancer cells
2008 C13
POLYMORPHISM GENE VARIATION POLYMORPHISM GENE VARIATION
66delG MT-DLOOP 66delG MT-DLOOP
309insC MT-DLOOP 263 A > G MT-DLOOP
315insC MT-DLOOP 315insC MT-DLOOP
379 A>T 379 A > T
709 G>A MT-RNR1 non cod 709 G > A MT-RNR1 non cod
1438 A >G MT-RNR1 non cod 1438 A > G MT-RNR1 non cod
1888 G > A MT-RNR2 non cod 1888 G > A MT-RNR2 non cod
4769 A > G MT-ND2 syn 4769 A > G MT-ND2 syn
6734 G > A MT-CO1 syn 6734 G > A MT-CO1 syn
8860 A > G MT-ATP6 T-A 8156 heteroplasmy
G > T*
MT-CO2 V-L
LD = 0,5315287 T > C MT-CYB F-L
15326 A > G MT-CYB T-A 8860 A > G MT-ATP6 T-A
16519 T > C MT-DLOOP 12018 heteroplasmy
C > T**
MT-ND4 T-I
LD = 0,69
13828 heteroplasmy
C > T**
MT-ND5 L-P
LD = 0,05
14470 T > A MT-ND6 syn
15287 T > C MT-CYB F-L
15326 A > G MT-CYB T-A
16519 T > C MT-DLOOP
*30% of mtDNA polymorphism rate in C13compared 
to 2008 cells.
**50% of mtDNA polymorphism rate in C13 compared 
to 2008 cells.
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of glutamine-derived carbons into glutamate, succinate, 
fumarate and malate was significantly higher in cisplatin-
resistant cells (Figure 4B). These results suggest that in the 
presence of deregulated mitochondrial function, glutamine 
becomes a privileged source of carbon for C13 cells. 
In line with a functional relevance of glutamine, C13 cells, 
differently from 2008 cells, showed a marked decrease in 
cell proliferation when cultured in glutamine-free media 
(Figure 4C and 4D).
Besides being a carbon source for the TCA 
cycle, glutamine is a key precursor of glutamate, 
required, among many functions, for the biosynthesis 
of glutathione (GSH), a major redox buffer in the cells. 
GSH has been proposed as an important molecule to 
sustain cisplatin resistance, and the overexpression 
of enzymes involved in GSH biosynthesis has been 
documented in these cells [23]. Although GSH vs 
GSSG ratio was similar between C13 and 2008 cells 
(Supplementary Table 1), the amount of GSH and GSSG 
was significantly higher in C13 cells (Figure 5A–5B). 
Of note, the contribution of glutamine to GSH was 
increased in C13 cells (Figure 5C), suggesting that a 
portion of glutamine is used by cisplatin-resistant cells 
to sustain GSH biosynthesis. These results indicate that 
the metabolic reprogramming of cisplatin-resistant cells 
may contribute to redox buffering.
Figure 1: Mitochondrial function in cancer cisplatin-resistant cells and their derived cybrids. A. Oxygen consumption of 
ovarian cancer cells (2008-C13) and their derived cybrids (H2008-HC13). B. Representative plots of the mitochondrial potential (ΔΨm) 
measured by flow cytometry. C. Effect of 5 mM galactose and D. 0.1 μM rotenone on cell viability after 24 hours of treatment. Data are 
expressed as percentage of cell number compared to the relative control. The data were obtained from at least 3–5 independent cultures. 
***p < 0.001, **p < 0.01, *p < 0.05; C13 vs 2008. +++p < 0.001, ++p < 0.01, +p < 0.05; treatment vs control.
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Inhibition of glucose-6-phosphate  
dehydrogenase (G6PDH) sensitizes  
cisplatin-resistant cells
Several lines of evidence suggest that, to maintain 
redox homeostasis, cancer cells engage into the PPP, a 
major source of NADPH for the cells. We hypothesized 
that, in addition to increasing GSH biosynthesis, C13 
cells might exploit the PPP pathway to compensate for the 
increased oxidative stress. G6PDH is a major checkpoint 
for the activity of the PPP. Interestingly, G6PDH mRNA 
(Figure 5D), protein expression (Figure 5E) and activity 
(Figure 5F), were increased in C13 cells, when compared to 
2008. To better understand the relevance of this metabolic 
Figure 2: Cisplatin-resistant cells present a reduced mitochondrial mass. A. Representative confocal images of Mitotracker 
Green (MTG) staining. B. Representative plots of Acridine Orange 10-Nonyl bromide (NAO) mean fluorescence intensity measured by flow 
cytometry.C. MTG mean fluorescence intensity, calculated after a volumetric reconstruction of the mitochondrial network. D. Expression 
levels of genes involved in mitochondrial biogenesis or F. in mitophagy as tested by qRT-PCR. All genes were normalized to β-actin as 
endogenous control. E. LC3 protein expression measured from western blotting. The data were obtained from at least 3–5 independent 
cultures. ***p < 0.001, **p < 0.01, *p < 0.05; C13 vs 2008.
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pathway in cisplatin resistance, cells were incubated with a 
combination of 6-aminonicotinamide (6-AN, competitive 
G6PDH inhibitor [24]) or dehydroepiandrosterone 
(DHEA, uncompetitive G6PDH inhibitor [25]) and 
cisplatin at concentrations lower than IC50. In order 
to appropriately assess the effects of the combination 
of 6-AN or DHEA and cisplatin, we performed 
isobolographic analysis. The linearity of the iso-effective 
concentrations producing 25% of cytotoxic effect strongly 
indicates additivity (Figure 5G–5H). On the contrary, the 
cytotoxic effect on 2008 was only due to the prevalent 
cisplatin activity, which hindered the overall effect, so 
an isobolograph could not be generated. Of note also in 
A431pt G6PDH expression and mRNA were increased 
when compared to A431 (Supplementary Figure 3A–3B) 
similarly to C13. By performing isobolographic analysis 
on iso-effective concentrations of cisplatin and 6-AN 
or DHEA producing 25% of cytotoxic effect, in A431pt 
cells, the observed curves deviate from the theoretical 
line show additivity for 6-AN and a modest synergism for 
DHEA (Supplementary Figure 3C–3D). Taken together, 
these results suggest that cisplatin-resistant cells exploit 
the oxidative PPP as a resistance mechanism. Both 
resistant cell lines did not show cross-resistance with 
other chemotherapeutic agents, including paclitaxel and 
doxorubicin (see Supplementary Figure 4).
DISCUSSION
Cisplatin cytotoxicity has been originally ascribed 
to interactions between cisplatin and nuclear DNA, 
which lead to the formation of adducts that activate 
Figure 3: Cisplatin-resistant cells show an increased dependency to glucose. A. Glucose uptake measured after incubation 
with the glucose analogue 6-NBDG. Data are normalized to cisplatin-sensitivecells. B. Expression levels of glycolytic genes measured by 
qRT-PCR. All genes were normalized to β-actin. C–D. Cell viability after 24 hours of glucose deprivation with (D) or without (C) 1 mM 
2-DG. Data are expressed as percentage of cell number compared to control. The data were obtained from at least 3–4 independent cultures. 
***p < 0.001, **p < 0.01, *p < 0.05; C13 vs 2008. +++p < 0.001; treatment vs control.
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the apoptotic machinery [2]. More recent data suggest 
that only 5–10% of cisplatin is bound to DNA, whilst 
other nucleophilic molecules such as phospholipids, 
cytoskeletal and membrane proteins, and mtDNA are 
targeted by the drug, suggesting that other mechanisms 
may explain cisplatin toxicity [26, 27]. Unfortunately, 
the therapeutic effectiveness of cisplatin is limited by the 
onset of cisplatin resistance [7], whose mechanisms are 
still not fully understood. Emerging evidence supports the 
idea that the deregulated cell metabolism could sustain 
drug resistance [28]. In this work we have investigated 
the contribution of metabolic reprogramming to cisplatin 
resistance and revealed novel metabolic liabilities of 
cisplatin-resistant cells.
Our previous research showed that cisplatin-
resistant ovarian cancer cells (C13) present defective 
mitochondrial bioenergetics [12, 20]. By generating 
transmitochondrial hybrids [29, 30, 31] we demonstrate 
here that the mitochondrial polymorphisms found in C13 
cells are not causative of the different mitochondrial asset 
previously observed. We also show that C13 mitochondrial 
dysfunction is not due to inherent respiratory chain defects 
but, rather, by a decrease in mitochondrial biomass. The 
increased mitochondrial turnover may be required to clear 
dysfunctional mitochondria that accumulate in cancer 
cells, and to maintain mitochondrial metabolism, as 
recently proposed by Strohecker et al. [32]. In line with 
these findings, we observed that the metabolic activity 
Figure 4: Cisplatin-resistant cells present an increased dependency on glutamine for TCA intermediates 
biosynthesis. A. Abundance of TCA intermediates measured using LC-MS normalised to total ion current. B. Incorporation of 13C-labelled 
carbons into glutamate, succinate, fumarate and malate after growing cells for 24 hours in the presence of [U-13C]glutamine. C–D. Effect 
of glutamine deprivation on 2008 (C) and C13 (D) cell viability measured by trypan blue exclusion assay. The data were obtained from at 
least three independent cultures. ***p < 0.001, *p < 0.05; C13 vs 2008. +++p < 0.001, ++p < 0.01; treatment vs control.
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Figure 5: Redox homeostasis is required for survival of C13 cisplatin-resistant cells. A–B. Cellular GSH and GSSG content 
measured by enzymatic assay (A) and GSH abundance (normalised to total ion count) measured by LC-MS (B). C. Intracellular levels 
of 13C5-GSH after growing cells for 24 hours in the presence of [U-
13C]glutamine. Data are normalized on the total pool of intracellular 
GSH (B) D. G6PD mRNA levels quantified by qRT-PCR, E. protein expression measured by western blotting and F. G6PDH enzymatic 
activity of 2008 and C13 cells. G–H. Isobologram of cisplatin-resistant cells showing additive effect of 6-AN or DHEA in association with 
cisplatin treatment. Data are expressed as percentage of cell number compared to control. The graph was obtained using iso-effective drug 
concentrations causing 25% of cytotoxic effect. Straight line indicates the theoretical additivity line. The data were obtained from at least 
3–5 independent cultures. ***p < 0.001, **p < 0.01, *p < 0.05; C13 vs 2008. +++p < 0.001; treatment vs control.
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of C13 cells measured by incubating cells with [U-13C]
glutamine is even higher than the cisplatin-sensitive 
counterpart. Therefore, our results suggest that a high 
mitochondrial turnover could compensate for inherent 
mitochondrial defects in cisplatin-resistant cells.
We then analyzed other aspects of the metabolic 
reprogramming of cisplatin-resistant cells, including 
glycolysis, glutaminolysis, and metabolic pathways 
involved in redox homeostasis. Cisplatin-resistant cells 
exhibited increased glucose uptake, overexpression of the 
glucose transporter GLUT1, and increased glutaminolysis, 
which make these cells more sensitive to glucose and 
glutamine deprivation. It is worth noting that glucose 
and glutamine are not mere carbon sources but they also 
contribute to the redox homeostasis of these cells. The 
activation of antioxidant pathways is now emerging as a 
crucial adaptive mechanism involved in drug resistance 
and a role for increased GSH biosynthesis has been 
proposed to provide resistance to cisplatin [23, 33, 34]. 
Consistent with this view, we found that glutamine-
derived glutamate is utilized for GSH biosynthesis in 
cisplatin-resistant cells. In support of a metabolic rewiring 
of glucose towards antioxidant pathways, we found that 
the expression and enzymatic activity of G6PDH, a key 
enzyme of the PPP, were elevated in resistant cells as 
compared to sensitive cells. Moreover, the combined 
treatment with the G6PDH inhibitors 6-AN or DHEA 
and cisplatin, showed a selective additive effect on 
cisplatin-resistant cells, suggesting that upregulation 
of G6PDH activity could be a targetable mechanism of 
chemotherapeutic resistance to cisplatin. In leukemia 
cells, it has been documented that the acquisition of 
daunorubicin resistance is accompanied by elevation 
of the oxidative PPP. But adriamycin/doxorubicin-
resistant MCF-7 cells display reduced G6PDH and PPP 
activity compared with sensitive cells, suggesting that a 
hyperactive PPP sensitizes cells to anthracyclines [17]. 
Differently from the contradictory results obtained with 
anthracyclines, our data clearly indicate that the PPP 
inhibition may be peculiar for cisplatin resistance, offering 
a novel synthetic lethality approach. These results are in 
line with the concept of induced essentiality, where by 
cancer cells become sensitive to the inhibition of the very 
same metabolic pathways that evolved as mechanisms of 
resistance from chemotherapeutic agents [35, 36].
Taken together our results show that profound 
metabolic changes underpin cisplatin resistance. Besides 
reduction of mitochondrial mass and overall mitochondrial 
function, these cells increase their demand of glucose and 
glutamine, which are in part used to maintain the cell’s 
antioxidant defenses. Chemotherapy designed to target 
metabolic pathways is a new approach, and potentially 
more effective to inhibit tumor cell growth [37]. Our work 
demonstrated that the combination of cisplatin treatment 
with inhibition of the PPP enzyme G6PDH, can remarkably 
improve the cytotoxic effects of cisplatin and can help to 
overcome cancer resistance to cisplatin treatment.
MATERIALS AND METHODS
Cell lines
Human ovarian carcinoma cell lines (2008 wild 
type and C13 cisplatin-resistant cells) were grown in 
Roswell Park Memorial Institute medium (RPMI 1640) 
supplemented with 10% fetal bovine serum (FBS), 
4 mM glutamine, 100 U/ml penicillin and 100 μg/ml 
streptomycin, in humidified condition at 5% CO2 and 37°C.
206-ρ° cells derived from mtDNA depletion of 
143B-TK− osteosarcoma cells (kind gift of Andrea 
Martinuzzi, IRCSS E. Medea-La Nostra Famiglia 
association) were cultured as previously described [38].
Transmitochondrial cybrid cell lines (H2008 and 
HC13) were generated by polyethylene glycol fusion 
of enucleated 2008 and C13 with the mtDNA-less (ρ0) 
osteosarcoma (143B-TK−) cell line as previously described 
[38]. Individual hybrid clones were isolated 10–20 days 
later using glass cylinders. Hybrid cell lines were cultured 
as previously described [39]. All reagents for cell culture 
were from Cambrex-Lonza (Basel, Switzerland) and FBS 
from Gibco, Invitrogen (Carlsbad, CA, USA).
Genome sequences
The entire mitochondrial genome was sequenced 
in a series of overlapping fragments using M13-tagged 
oligodeoxynucleotide primers to facilitate direct sequencing 
of the PCR amplified products with BigDye®terminator 
chemistries on an Applied Biosystem 3100 automated 
sequencer (Applied Biosystems, Warrington, UK) [40]. 
All sequences were directly compared to the revised 
Cambridge reference sequence for human mtDNA 
(GenBank Accession number NC_012920).
Cell viability assays
Trypan blue exclusion assay
2 × 105 cells (2008-C13) or 1 × 105 cells (H2008-
HC13) were plated on 6-well plates and, following 
overnight incubation, were exposed to different treatments 
according to experimental protocols. After treatments, 
cells were washed, detached with 0.25% trypsin-0.2% 
EDTA and suspended in trypan blue (Sigma-Aldrich, 
St Louis, MO, USA) at 1:1 ratio in medium solution. Cells 
were counted using a chamber Burker hemocytometer.
Sulforhodamine B (SRB) test
2.5 × 103 cells were plated on 96-well plates 
and, following overnight incubation, were exposed to 
different treatments according to experimental protocols. 
After treatments cells were fixed to tissue-culture plates 
with trichloroacetic acid (Sigma-Aldrich) and stained 
for 30 minutes with SRB (Sigma-Aldrich). The bound 
SRB was dissolved by adding 160 μl of 10 mM TRIS 
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(pH = 10.5) and the absorbance was measured at 570 nm 
using a Victor3X multilabel plate counter (Wallac 
Instruments, Turku, Finland).
Annexin V/propidium iodide staining
1 × 105 cells (H2008-HC13) were seeded in 12-well 
plates, incubated overnight and treated with cisplatin 
(1–10 μM) for 24 hours. Then, cells were harvested by 
quick trypsinization and centrifugated at 1200 rpm for 
5 minutes. The cell pellet was resuspended in a binding 
buffer containing Alexa Fluor 488 Annexin V and 
propidium iodide (Molecular Probes, Invitrogen, Carlsbad, 
CA, USA) and then incubated for 15 minutes at room 
temperature as previously described [12]. The fluorescence 
of stained cells was measured by Epics XL flow cytometer 
(Coulter Systems, Fullerton, CA, USA) and analysed 
with the EXPO 32 software (Coulter Systems, Fullerton, 
CA, USA).
Oxygen consumption
Oxygen consumption was measured in live cells 
(3.5 × 106) resuspended in 1 ml glucose-free DMEM 
(Gibco, Invitrogen) supplemented with 10% sodium-
pyruvate (Cambrex-Lonza) at 37°C, using a Clark-type 
oxygen electrode (Hansatech Instruments, King’s Lynn, 
Norfolk, UK). Oxygen consumption was measured using 
the software Oxygraph plus v. 1.01. Data processing 
includes: fmol/c/min = (RATE/3.5 × 106)*1 million.
Mitochondrial membrane potential (ΔΨ) 
and mitochondrial mass
Flow cytometry
2 × 105 cells (2008-C13) or 1 × 105 cells (H2008-
HC13) were seeded and incubated for 48 hours, washed 
with phosphate buffer saline solution (PBS), detached 
with 0.25% trypsin-0.2% EDTA and centrifuged for 
5 minutes at 1200 rpm. Cells were resuspended with 
rhodamine-123 (10 μM) or Acridine Orange 10-Nonyl 
bromide NAO (25 nM) and incubated for 15 minutes. 
Probes were from Sigma-Aldrich. Fluorescence intensity 
was analyzed using an Epics XL flow cytometer. 104 cells 
of interest were analyzed. Mean fluorescence intensity 
(MFI) values were obtained using the EXPO 32 software.
Live-cells confocal microscopy
2 × 105 cells (2008-C13) or 1 × 105 cells (H2008-
HC13) were grown in 3.5 cm glass-bottom dishes 
(MatTek Corporation, Ashland, USA) and, after 48 hours, 
were loaded with 100 nM Mitotracker Green (MTG; 
Invitrogen). Cells were imaged using a laser scanner 
microscope (Leica TCS SP5, 60X magnification). 
A volumetric reconstruction was then obtained and 
analysed using the software Volocity.
Immunoblot assay
1.5 × 106 cells (2008-C13) were plated in 100 mm 
cell culture dish and allowed to attach overnight. After 
48 hours, cells were lysed with ice-cold lysis buffer 
supplemented with the protease inhibitor cocktails (Roche 
Molecular Biochemicals, Mannheim, Germany). The 
protein content was determined by Lowry procedure 
(Bio-rad DC Protein Assay, MA, USA). Equal amounts 
of protein (40 μg) were loaded on a polyacrylamide gel 
and electrophoretically separated in running buffer. 
After electrophoresis, the proteins were blotted onto an 
Hybond-P PVDF membrane (Amersham Biosciences, 
Buckinghamshire, UK). After blocking, the membrane 
was exposed to the elected primary antibodies: anti-LC3 
(1:1000; Cell Signaling, MA, USA) or anti-G6PD (1:500; 
Santa Cruz Biotechnology, Inc., Europe). After washing, 
the membrane was incubated with HRP-conjugated 
anti-rabbit secondary antibody (1:3500; PerkinElmer, 
MA,USA). The signal was visualized with enhanced 
chemoluminescent kit (Amersham Biosciences) according 
to the manufacturer’s instructions and analyzed by 
Molecular Imager VersaDoc MP 4000 (Bio-rad). LC3 and 
G6PD were normalized to beta-actin (1:7000; AbCam, 
Cambridge, UK).
Quantitative real-time PCR
Total mRNA was isolated as per manufacturer’s 
instructions using QIAshredder and RNeasykits (Qiagen, 
Venlo, Netherlands) and measured with a NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Inc. 
Wilmington, DE, USA). 0,5 μg of total mRNA was reverse-
transcribed to complementary DNA using The High 
Capacity cDNA Reverse Transcription Kits of Applied 
Biosystem by Life Technologies. The relative expression of 
genes of interest was determined by quantitative real-time 
PCR (StepOne™ Systems of Applied Biosystem by Life 
Technologies) using Power SYBR® Green PCR Master Mix 
(Applied Biosystem by Life Technologies) and the primers 
designed as follow: BNIP3: F gaatttctgaaagttttccttcca 
R ttgtcagacgccttccaata; GLUT1: F ttaactccacccacctcct, R 
ccaaatcggcatcttctcat; PFKM: F gccatcagcctttgacaga, 
R ctccaaaagtgccatcactg; PGK1: F cagctgctgggtctgtcat, 
R gctggctcggctttaacc; LDHA: F aaaccgtgttattggaagcg, 
R agcactctcaaccacctgct. To measure the mRNA level 
of G6PDH and mitochondrial biogenesis genes, total 
mRNA was isolated with TRIzol (Life Technologies) 
as previously described by Chomczynski P and Sacchi 
N [42] and measured with a Beckman Coulter DU-800 
spectrophotometer. The relative expression of each gene 
was determined by quantitative real-time PCR (Eco™ 
Illumina, Real-Time PCR system, San Diego, CA, 
USA) using One Step SYBR PrimeScript RT-PCR Kit 
(Takara Bio, Inc., Otsu, Shiga, Japan) and the primers 
designed as follow: G6PDH: F aagaacgtgaagctccctga 
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R aatataggggatgggcttgg; PGC-1α: F acacagtcgcagtcacaacac 
R ggagtggtgggtggagttagg; PGC-1β: F gcacctcacctcggcacag 
R cggctccttgtcctccttgg; NRF1: F gtaaccctgatggcactgtctc 
R gcttgcgtcgtctggatgg; NRF2: F ttccttcagcagcatcctctcc R 
aatctgtgttgactgtggcatctg; Tfam: F aacaacgaaaatatggtgctgagg 
R caagtattatgctggcagaagtcc. Linearity and efficiency of 
PCR amplifications were assessed using standard curves 
generated by serial dilution of complementary DNA; 
melt-curve analysis was used to confirm the specificity 
of amplification and absence of primer dimers. All 
genes were normalized to β-actin designed as follow: F 
ccaaccgcgagaagatga R ccagaggcgtacagggatag. Expression 
levels of the indicated genes were calculated by the ΔΔCt 
method using respectively the dedicated StepOne software 
or Eco™ Software v4.0.7.0.
Liquid chromatography-mass spectroscopy  
(LC-MS)
2 × 105 cells (2008-C13) were plated in 6-well plates 
and after 48 hours quickly washed with ice cold PBS 
on an ice bath. The samples were therefore prepared as 
previously described [43]. In brief, cells were lysed with a 
dry ice/methanol solution (−80°C) of 50% methanol/30% 
acetonitrile in water and quickly scraped. The extracts 
were mixed at 4°C for 15 minutes and pelleted in a cooled 
centrifuge (4°C). The supernatant was collected and 
submitted for LC-MS analysis. The amount of extraction 
solution was calculated according to the number of cells 
present in the sample dish, extrapolated using a “counter 
dish” cultured in the same conditions of the sample dishes. 
A concentration of 1 ml per 1 × 106 cells was used in the 
extraction solutions.
Intermediates were separated using a liquid 
chromatography system. Data acquisition was controlled 
with Xcalibur 2.0 (ThermoElectron Co, San Jose, CA, 
USA). The mass accuracy was maintained below 1 ppm 
due to use of a lock mass. The raw chromatograms 
were then aligned using the software SIEVE™ 
(ThermoElectron). The integration of the measured ion 
current over a metabolite’s elution time and m/z interval 
is directly proportional to its absolute abundance in 
the solution. We manually removed from the SIEVE’s 
output unspecific and misaligned peaks to eliminate 
the noise.
Glucose uptake
5 × 103 cells (2008-C13) were plated in 96-well 
plate and allowed to attach overnight. After 24 hours, 
glucose uptake was measured by incubating cells with 
90 μM glucose analogue 6-NBDG (Invitrogen, Paisley, 
UK) for 1 minute. Cells where then washed, added with 
PBS and their fluorescence (λex: 465 nm, λem: 540nm) 
was measured by Victor3X multilabel plate counter 
(Wallac Instruments).
GSH/GSSG
Cellular GSH and GSSG content was enzymatically 
determined as previously described by Floreani et al. 
[44]. 1.5 × 106 cells (2008-C13) were plated in 100 
mm cell culture dish and allowed to attach overnight. 
After 48 hours, cells were washed with PBS and then 
treated with 6% meta-phosphoric acid (MPA). After 
10 minutes at room temperature, the acid extract was 
collected, centrifuged for 5 minutes at 14000 rpm and 
processed. The cellular pellet was solubilized with 0.5 M 
potassium hydroxide and assayed for protein content. 
For total GSH determination, the above acid extract was 
diluted in 6% MPA and added with 0.1 M potassium 
phosphate/5 mM EDTA buffer (pH 7.4), 10 mM 5,5-dithiobis- 
(2-nitrobenzoic acid) and 5 mM NADPH. After a 3 minute 
equilibration period, the reaction was started by adding 
2 U GSH reductase (type III; Sigma-Aldrich; from baker’s 
yeast; diluted in 0.1 M phosphate/EDTA buffer). Product 
formation was recorded continuously at 412 nm with a 
Beckman DU800 UV-Vis spectrophotometer. The total 
amount of GSH was determined from a standard curve 
obtained by plotting known amounts of GSH against the 
rate of change in absorbance. For GSSG measurement, 
soon after preparation, the supernatant of acid extract 
was treated for derivatization with 2-vinylpyridine and 
triethanolamine. The samples were incubated at room 
temperature for 60 minutes and then assayed with the same 
procedure above described for total GSH measurement. 
The GSH concentration of each sample was calculated as 
the difference between total glutathione and GSSG. All 
reagents were from Sigma-Aldrich.
G6PDH activity
1.5 × 106 cells (2008-C13) were plated in 100 mm 
cell culture dish and allowed to attach overnight. After 
48 hours, cells were washed with PBS and quickly scraped. 
2.5 × 106 of cells were then collected by centrifugation 
and sonicated on ice. The G6PDH activity was assayed 
on cell supernatant as per manufacturer’s instructions 
using the Glucose-6-Phosphate Dehydrogenase Activity 
Assay Kit (Cayman Chemical Company, MI, USA). The 
fluorescence intensity (λex/em = 540/585) was measured 
using a Victor3X multilabel plate counter (Wallac 
Instruments). The G6PDH activity (nmol/min/ml) was 
calculated as per manufacturer’s instructions.
Statistical analyses
All data are expressed as mean ± SEM. Standard 
ANOVA procedures followed by multiple pairwise 
comparison adjusted with Bonferroni corrections were 
performed for cell viability assays. Unpaired Student’s 
t-tests were used to analyse all the other results. 
Significance was considered at p < 0.05.
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Isobolographic analysis
Isobolographic analysis was used to determine 
the effect of the combination between cisplatin and the 
G6PDH inhibitor 6-AN or DHEA. Isoboles are defined as 
iso-effect curves that show drug concentrations resulting 
in equal effect [45, 46]. From iso-effective curves it 
is possible to verify the presence of simple additivity, 
supra-additivity (synergism, i.e. when drug combination 
produces an effect greater than that predictable from 
each drug alone) or infra-additivity (antagonism). 
Isobolographic analysis was possible only for C13 
and A431pt data; in 2008 cells the predominant effect 
produced by cisplatin hindered the overall effect.
ACKNOWLEDGMENTS
We thank Stefano Lovison for computer assistance.
FUNDING
This work was financially supported by PRAT 
(University of Padova), grant no. CPDA124517/12 
and MIUR grant no 60A04–0443. DC fellowship was 
supported by grant no. CPDR134012. AR was supported 
by the AIRC grant no. IG 15863 and by the University of 
Padova grant no. CPDA 123598.
CONFLICTS OF INTEREST
The authors declare no conflict of interest.
REFERENCES
1. Galanski M. Recent developments in the field of antican-
cer platinum complexes. Recent Patents Anticancer Drug 
Discovery. 2006; 1:285–95.
2. Wang D, Lippard S. Cellular processing of platinum anti-
cancer drugs. Nature Reviews Drug Discovery. 2005; 
4:307–320.
3. Preston TJ, Abadi A, Wilson L, Singh G. Mitochondrial 
contribution to cancer cell physiology: potential for drug 
development. Advanced Drug Delivery Reviews. 2001; 
49:45–61.
4. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, 
Kepp O, Castedo M, Kroemer G. Molecular mechanisms of 
cisplatin resistance. Oncogene. 2012; 31:1869–83.
5. Ciscato F, Sciacovelli M, Villano G, Turato C, Bernardi P, 
Rasola A, Pontisso P. SERPINB3 protects from oxida-
tive damage by chemotherapeutics through inhibition of 
mitochondrial respiratory complex I. Oncotarget. 2014; 
5:2418–27.
6. Pasetto LM, D’Andrea MR, Brandes AA, Rossi E, 
Monfardini S. The development of platinum compounds 
and their possible combination. Critical Reviews In 
Oncology. Hematology. 2006; 60:59–75.
7. Koberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin 
resistance: preclinical findings and clinical implications. 
Biochimica et Biophysica Acta. 2010; 1806:172–82.
8. Rabik CA, Dolan ME. Molecular mechanisms of resistance 
and toxicity associated with platinating agents. Cancer 
Treatment Reviews. 2007; 33:9–23.
9. Boulikas T, Vougiouka M. Cisplatin and platinum drugs 
at the molecular level. (Review). Oncology Reports. 2003; 
10:1663–82.
10. Shen DW, Pouliot LM, Hall MD, Gottesman MM. 
Cisplatin Resistance: A Cellular Self-Defense Mechanism 
Resulting from Multiple Epigenetic and Genetic Changes. 
Pharmacological Reviews. 2014; 64:706–721.
11. Kelland LR. Preclinical perspectives on platinum resistance. 
Drugs. 2000; 59:1–8. discussion 37-8.
12. Montopoli M, Ragazzi E, Froldi G, Caparrotta L. Cell-cycle 
inhibition and apoptosis induced by curcumin and cispla-
tin or oxaliplatin in human ovarian carcinoma cells. Cell 
Proliferation. 2009; 42:195–206.
13. Ishikawa T, Ali-Osman F. Glutathione-associated cis-
diamminedichloroplatinum (II) metabolism and ATP-
dependent efflux from leukemia cells. Molecular char-
acterization of glutathione-platinum complex and its 
biological significance. Journal of Biological Chemistry. 
1993; 268:20116–20125.
14. Vander Heiden MG, Cantley LC, Thompson CB. 
Understanding the Warburg Effect: The Metabolic 
Requirements of Cell Proliferation. Science. 2009; 
324:1029–1033.
15. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next 
Generation. Cell. 2011; 144:646–674.
16. Menedez JM. Fine-tuning the lipogenic/lipolytic balance to 
optimize the metabolic requirements of cancer cell growth: 
molecular mechanisms and therapeutic perspectives. 
Biochimica et Biophysica Acta. 2010; 1801:381–391.
17. Patra KC, Hay N. The pentose phosphate pathway and 
 cancer. Trends in Biochemical Sciences. 2014; 39:347–354.
18. Saiati LM, Amir-Ahmady B. Dietary regulation of expres-
sion of glucose-6-phosphate dehydrogenase. Annual 
Review of Nutrition. 2001; 21:121–40.
19. Jiang P, Du W, Wu M. Regulation of the pentose phosphate 
pathway in cancer. Protein Cell. 2014; 5:592–602.
20. Montopoli M, Bellanda M, Lonardoni F, Ragazzi E, 
Dorigo P, Froldi G, Mammi S, Caparrotta L. “Metabolic 
reprogramming” in ovarian cancer cells resistant to 
 cisplatin. Current Cancer Drug Targets. 2011; 11:226–35.
21. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, 
Sachdeva UM, Platt JM, DeMatteo RG, Simon MC, 
Thompson CB. Hypoxia promotes isocitrate dehydrogenase-
dependent carboxylation of α-ketoglutarate to citrate to sup-
port cell growth and viability. Proceedings of the National 
Academy of Science. 2011; 108:19611–19616.
22. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, 
Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, 
Oncotarget30114www.impactjournals.com/oncotarget
Guarente L, Kelleher JK, Vander Heiden MG, 
Iliopoulos O, et al. Reductive glutamine metabolism by 
IDH1 mediates  lipogenesis under hypoxia. Nature. 2012; 
481:380–384.
23. Byun SS, Kim SW, Choi H, Lee C, Lee E. Augmentation 
of cisplatin sensitivity in cisplatin-resistant human bladder 
cancer cells by modulating glutathione concentrations and 
glutathione-related enzyme activities. BJU International. 
2005; 95:1086–90.
24. Köhler E, Barrach H, Neubert D. Inhibition of NADP 
dependent oxidoreductases by the 6-aminonicotinamide 
analogue of NADP. FEBS Letters. 1970; 6:225–8.
25. Raineri R, Levy HR. On the specificity of steroid interaction 
with mammary gland glucose-6-phosphate dehydrogenase. 
Biochemistry. 1970; 9:2233–43.
26. Jordan P, Carmo-Fonseca M. Molecular mechanisms 
involved in cisplatin cytotoxicity. Cellular and Molecular 
Life Sciences. 2000; 57:1229–35.
27. Arnesano F, Natile G. “Platinum on the road”: interactions 
of antitumoral cisplatin with proteins. Pure and Applied 
Chemistry. 2008; 80:2715–2725.
28. Liu H, Liu Y, Zhang JT. A new mechanism of drug 
resistance in breast cancer cells: fatty acid synthase 
 overexpression-mediated palmitate overproduction. 
Molecular Cancer Therapeutics. 2008; 7:263–270.
29. Sala G, Trombin F, Beretta S, Tremolizzo L, Presutto P, 
Montopoli M, Fantin M, Martinuzzi A, Carelli V, 
Ferrarese C. Antioxidants partially restore glutamate trans-
port defect in Leber hereditary optic neuropathy cybrids. 
Journal of Neuroscience Research. 2008; 86:3331–7.
30. Kaipparettu BA, Ma Y, Wong LJ. Functional effects 
of  cancer mitochondria on energy metabolism and 
 tumorigenesis: utility of transmitochondrial cybrids. 
Annals of the New York Academy of Sciences. 2010; 
1201:137–46.
31. Perli E, Giordano C, Tuppen HA, Montopoli M, 
Montanari A, Orlandi M, Pisano A, Catanzaro D, 
Caparrotta L, Musumeci B, Autore C, Morea V, 
Di Micco P, et al. Isoleucyl-tRNAsynthetase levels 
modulate the penetrance of a homoplasmic m.4277T>C 
 mitochondrial tRNA(Ile) mutation causing hypertrophic 
cardiomyopathy. Human Molecular Genetics. 2012; 
21:85–100.
32. Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, 
Chen GJ, Mathew R, McMahon M, White E. Autophagy 
sustains mitochondrial glutamine metabolism and growth 
of BrafV600E-driven lung tumors. Cancer Discovery. 2013; 
3:1272–85.
33. Lustberg MB, Edelman MJ. Optimal duration of 
 chemotherapy in advanced non-small cell lung cancer. 
Current Treatment Options in Oncology. 2007; 8:38–46.
34. Tai DJ, Jin WS, Wu CS, Si HW, Cao XD, Guo AJ, 
Chang JC. Changes in intracellular redox status  influence 
multidrug resistance in gastric adenocarcinoma cells. 
Experimental and Therapeutic Medicine. 2012; 4:291–296.
35. Blagosklonny MV. Oncogenic resistance to growth-limiting 
conditions. Nature Reviews Cancer. 2002; 2:221–5.
36. Blagosklonny MV. NCI’s provocative questions on  cancer: 
some answers to ignite discussion. Oncotarget. 2011; 
2:1352–67.
37. Ramos-Montoya A, Lee WN, Bassilian S, Lim S, 
Trebukhina RV, Kazhyna MV, Ciudad CJ, Noé V, 
Centelles JJ, Cascante M. Pentose phosphate cycle oxida-
tive and nonoxidative balance: A new vulnerable target for 
overcoming drug resistance in cancer. International Journal 
of Cancer. 2006; 119:2733–41.
38. King MP, Attardi G. Human cells lacking mtDNA: repopu-
lation with exogenous mitochondria by complementation. 
Science. 1989; 246:500–3.
39. Giordano C, Montopoli M, Perli E, Orlandi M, Fantin M, 
Ross-Cisneros FN, Caparrotta L, Martinuzzi A, Ragazzi E, 
Ghelli A, Sadun AA, D’Amati G, Carelli V. Oestrogens 
ameliorate mitochondrial dysfunction in Leber’s hereditary 
optic neuropathy. Brain. 2011; 134:220–34.
40. Tuppen HA, Fehmi J, Czermin B, Goffrini P, Meloni F, 
Ferrero I, He L, Blakely EL, McFarland R, Horvath R, 
Turnbull DM, Taylor RW. Long-term survival of neona-
tal mitochondrial complex III deficiency associated with 
a novel BCS1L gene mutation. Molecular Genetics and 
Metabolism. 2010; 100:345–8.
41. Mussini C, Pinti M, Bugarini R, Borghi V, Nasi M, Nemes E, 
Troiano L, Guaraldi G, Bedini A, Sabin C, Esposito R, 
Cossarizza A. Effect of CD4-monitored treatment interrup-
tion on mitochondrial DNA content in HIV-infected patients: 
a prospective study. AIDS. 2005; 19:1627–33.
42. Chomczynski P, Sacchi N. Single-step method of RNA iso-
lation by acid guanidiniumthiocyanate-phenol-chloroform 
extraction. Analytical Biochemistry. 1987; 162:156–9.
43. Yizhak K, Gaude E, Le Dévédec S, Waldman YY, Stein GY, 
van de Water B, Frezza C, Ruppin E. Phenotype-based cell-
specific metabolic modeling reveals metabolic liabilities of 
cancer. Elife. 2014; 3. doi: 10.7554/eLife.03641.
44. Floreani M, Petrone M, Debetto P, Palatini P. A compari-
son between different methods for the determination of 
reduced and oxidized glutathione in mammalian tissues. 
Free Radical Research. 1997; 26:449–55.
45. Loewe S. The problem of synergism and antagonism of 
combined drugs. Arzneimittelforschung. 1953; 3:285–90.
46. Tallarida RJ. An overview of drug combination analy-
sis with isobolograms. Journal of Pharmacology and 
Experimental Therapeutics. 2006; 319:1–7.
